
Orazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses enzalutamide plus docetaxel combination for the frontline treatment of metastatic castration-resistant prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Published: June 17th 2019 | Updated: